Zimmer Biomet Holdings (ZBH) Stock Overview
Operates as a medical technology company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
ZBH Community Fair Values
Create NarrativeSee what 50 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Zimmer Biomet Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$87.97 |
| 52 Week High | US$108.29 |
| 52 Week Low | US$79.12 |
| Beta | 0.47 |
| 1 Month Change | 2.89% |
| 3 Month Change | 0.19% |
| 1 Year Change | -3.56% |
| 3 Year Change | -38.91% |
| 5 Year Change | -46.96% |
| Change since IPO | 195.60% |
Recent News & Updates
Seeking Alpha • Jun 16
Zimmer Biomet: Does Slow And Steady Still Win The Race?
Summary Zimmer Biomet Holdings trades at a steep valuation discount despite strong free cash flow and high margins. ZBH's entrenched position in orthopedic implants, robust cash generation, and loyal installed base underpin reliable earnings. Recent results show net sales up 9.3%, adjusted EPS up 15.5%, and adjusted gross margin rising to 73.0%. With manageable debt and ongoing buybacks, ZBH's current price compensates for its slow, steady growth profile. Read the full article on Seeking Alpha
Narrative Update • Jun 10
ZBH: Future Returns Will Hinge On Margin Execution And Robotics Expansion Potential
Zimmer Biomet Holdings' updated analyst price target edges higher to $98.70, even as several firms recently trimmed their individual targets and reiterated a generally neutral stance after revisiting models following Q1 results. Analyst Commentary Recent research points to a broadly cautious, wait and see stance on Zimmer Biomet, with several firms trimming price targets and reiterating neutral views after updating models following Q1 results.Narrative Update • May 27
ZBH: Future Returns Will Depend On Margin Execution Despite Recent Multiple Reset
Zimmer Biomet Holdings' updated analyst price target has edged down by about $4 to $98.52. Analysts cite slightly softer revenue growth assumptions, a lower expected future P/E multiple, and a modest adjustment to the discount rate, alongside a small improvement in projected profit margins.Recent updates
Seeking Alpha • Jun 16
Zimmer Biomet: Does Slow And Steady Still Win The Race?
Summary Zimmer Biomet Holdings trades at a steep valuation discount despite strong free cash flow and high margins. ZBH's entrenched position in orthopedic implants, robust cash generation, and loyal installed base underpin reliable earnings. Recent results show net sales up 9.3%, adjusted EPS up 15.5%, and adjusted gross margin rising to 73.0%. With manageable debt and ongoing buybacks, ZBH's current price compensates for its slow, steady growth profile. Read the full article on Seeking AlphaNarrative Update • Jun 10
ZBH: Future Returns Will Hinge On Margin Execution And Robotics Expansion Potential
Zimmer Biomet Holdings' updated analyst price target edges higher to $98.70, even as several firms recently trimmed their individual targets and reiterated a generally neutral stance after revisiting models following Q1 results. Analyst Commentary Recent research points to a broadly cautious, wait and see stance on Zimmer Biomet, with several firms trimming price targets and reiterating neutral views after updating models following Q1 results.Narrative Update • May 27
ZBH: Future Returns Will Depend On Margin Execution Despite Recent Multiple Reset
Zimmer Biomet Holdings' updated analyst price target has edged down by about $4 to $98.52. Analysts cite slightly softer revenue growth assumptions, a lower expected future P/E multiple, and a modest adjustment to the discount rate, alongside a small improvement in projected profit margins.Analysis Article • May 01
Results: Zimmer Biomet Holdings, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
It's been a mediocre week for Zimmer Biomet Holdings, Inc. ( NYSE:ZBH ) shareholders, with the stock dropping 11% to...Narrative Update • Apr 25
ZBH: Future Returns Will Hinge On U.S. Execution And Share Repurchases
The updated analyst price target for Zimmer Biomet Holdings ticks slightly lower to about $103 from roughly $103.05, as analysts factor in modestly different assumptions on discount rate, revenue, profit margin and future P/E while weighing a mix of new initiations, downgrades and recent target revisions across the Street. Analyst Commentary Recent Street research around Zimmer Biomet offers a mix of constructive and cautious views, with several firms initiating coverage around the middle of the rating spectrum and others adjusting price targets and ratings as they reassess execution risks and valuation.Narrative Update • Apr 09
ZBH: Future Returns Will Depend On U.S. Execution And Ongoing Buybacks
The updated analyst price target for Zimmer Biomet Holdings moves slightly higher to about $103.05, as analysts balance more cautious margin assumptions with modestly stronger long term growth and P/E expectations, alongside mixed recent rating changes and price target revisions across the Street. Analyst Commentary Recent Street research on Zimmer Biomet shows a mix of optimism and caution, with views split on how much execution risk and valuation upside remain at current levels.Narrative Update • Mar 26
ZBH: Future Returns Will Rely On U.S. Execution And Ongoing Share Repurchases
Analysts have made a small upward adjustment to the Zimmer Biomet Holdings fair value estimate, lifting the price target by about $0.35 to $103.00. Recent research reflects a balance between higher targets from some firms and downgrades that highlight concerns around execution and growth consistency.Narrative Update • Mar 12
ZBH: Future Returns Will Hinge On U.S. Execution And Share Repurchases
Zimmer Biomet Holdings' updated analyst price target remains close to prior levels at about $103, as analysts weigh modest P/E and discount rate adjustments alongside mixed research views that reflect both concern over growth consistency and a wait and see approach to U.S. commercial execution. Analyst Commentary Recent research on Zimmer Biomet shows a split between analysts who see the current share price as reasonable for a steady, de-risked story and those who are more concerned about growth consistency and execution, especially in the U.S. Bullish Takeaways Bullish analysts highlight that management has already factored potential 2026 disruption into forecasts, which they see as reducing the risk of major estimate resets.Narrative Update • Feb 26
ZBH: Future Returns Will Depend On Executing Commercial Reset And Share Repurchases
The analyst price target for Zimmer Biomet has been trimmed by about $0.30, reflecting slightly lower modeled fair value and profit margin assumptions as analysts weigh mixed ratings changes and look for clearer evidence that recent commercial and growth challenges are being addressed. Analyst Commentary Recent Street research presents a split view on Zimmer Biomet, with some analysts seeing room for upside as execution improves and others focusing on ongoing growth and margin constraints.Narrative Update • Feb 10
ZBH: Future Returns Will Rely On Executing Through Slower Organic Growth
Narrative Update Analysts have made a modest upward adjustment to their price target for Zimmer Biomet Holdings to around US$103. They cite slightly higher margin expectations, a lower assumed discount rate, and mixed recent research that includes both target trims and downgrades alongside fresh Buy and Market Perform views.Narrative Update • Jan 25
ZBH: Future Returns Will Depend On Pipeline Execution And Product Commercialization
Zimmer Biomet Holdings' fair value estimate has edged down by about $0.30 to $102.39, reflecting analysts' mixed price target revisions, with some trimming outlooks after softer organic growth and guidance resets, while others see potential improvement as sector sentiment steadies. Analyst Commentary Recent research shows a split picture on Zimmer Biomet, with some bullish analysts focusing on execution progress and product momentum, while more cautious voices highlight slowing organic growth and guidance resets.Narrative Update • Jan 09
ZBH: Future Returns Will Rely On Pipeline Delivery Versus Execution Setbacks
Narrative Update Zimmer Biomet Holdings' updated fair value estimate edges higher to about $102.70 per share from roughly $102.04, as analysts factor in slightly firmer revenue growth assumptions, a modestly higher future P/E of about 19.9x, and recent price target cuts that reflect frustration with inconsistent growth, mixed Q3 results, and tighter guidance. Analyst Commentary Recent Street research on Zimmer Biomet reflects a mix of concern about the near term growth profile and some ongoing confidence in the company’s product pipeline and commercial progress.Narrative Update • Dec 20
ZBH: Future Upside Will Depend On Delivering Pipeline And Portfolio Diversification
Zimmer Biomet Holdings’ fair value estimate has been trimmed by about $0.88 per share to roughly $102, as analysts lower price targets in the $93 to $112 range due to softer than expected organic growth, tightening guidance, and a more cautious multi year sales outlook, despite ongoing pipeline and portfolio progress. Analyst Commentary Street research following the Q3 update reflects a more balanced but cautious stance on Zimmer Biomet, with price targets reset lower and a growing focus on execution risk around the company’s multi year growth narrative.Narrative Update • Dec 06
ZBH: Future Returns Will Depend On Delivering Pipeline And Execution Improvements
Analysts have modestly reduced their average price targets for Zimmer Biomet by high single digits in dollar terms, reflecting tempered expectations for organic growth and near term execution after a mixed Q3, even as they acknowledge ongoing pipeline progress and portfolio diversification. Analyst Commentary Street research following the Q3 release reflects a more balanced and nuanced view of Zimmer Biomet, with modestly lower price targets and mixed rating actions signaling both frustration with execution and recognition of underlying strategic progress.Narrative Update • Nov 22
ZBH: Share Momentum Will Improve As New Product Launches Drive Recovery
Zimmer Biomet Holdings' analyst price target was reduced from approximately $104.84 to $102.92 per share. This change reflects cautious analyst sentiment following the company's mixed third-quarter results, tightening of guidance, and lowered growth expectations.Analysis Article • Nov 14
There May Be Some Bright Spots In Zimmer Biomet Holdings' (NYSE:ZBH) Earnings
The most recent earnings report from Zimmer Biomet Holdings, Inc. ( NYSE:ZBH ) was disappointing for shareholders...Narrative Update • Nov 07
ZBH: Share Momentum Will Return As Next-Gen Orthopedics Gain Wider Adoption
Zimmer Biomet Holdings' analyst price target has been reduced from approximately $111 to $105 per share. Analysts cite slower-than-expected revenue growth, continued profit margin pressure, and more cautious future business outlooks following disappointing quarterly results.Narrative Update • Sep 04
Aging Population And Robotics Will Elevate Orthopedic Care
Following stronger-than-expected Q2 results, raised guidance, and increased optimism about future earnings growth, analysts maintained Zimmer Biomet Holdings’ consensus price target at $110.92. Analyst Commentary Increased confidence in Zimmer Biomet’s second half performance following solid Q2 results.Analysis Article • Jul 22
Here's Why Zimmer Biomet Holdings (NYSE:ZBH) Can Manage Its Debt Responsibly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Jul 04
Many Still Looking Away From Zimmer Biomet Holdings, Inc. (NYSE:ZBH)
There wouldn't be many who think Zimmer Biomet Holdings, Inc.'s ( NYSE:ZBH ) price-to-earnings (or "P/E") ratio of...Seeking Alpha • Feb 07
Zimmer Biomet: Adding To The Growth Profile
Summary Zimmer Biomet shares at $105 reveal value at 13 times adjusted earnings, as the company continues to grow despite a GLP-1 drug overhang. The 2015 Zimmer Biomet merger hasn't been fully delivered, but recent organic growth and M&A actions are promising, with mid-single digit sales growth projected. The $1.2 billion Paragon 28 acquisition enhances foot and ankle orthopedics, despite short-term EPS dilution, and boosts Zimmer Biomet's growth profile. I remain optimistic on Zimmer Biomet due to continued organic growth, strategic acquisitions, and product approvals, supporting future valuation multiple inflation. Read the full article on Seeking AlphaSeeking Alpha • Jan 05
Zimmer Biomet: Back On Offense With Strong Cash Flow Outlook
Summary Zimmer Biomet Holdings (ZBH) is expanding its product portfolio and improving cash flow, positioning it for long-term profitability and financial health. ZBH is undervalued compared to peers, with significant growth potential driven by innovation, acquisitions, and operational efficiency improvements. The company's focus on high-growth markets and improving profitability metrics indicate a strong future outlook, despite past underperformance. ZBH's improving free cash flow and strategic investments make it an attractive buy ahead of its Q4 2024 report. Read the full article on Seeking AlphaShareholder Returns
| ZBH | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -0.7% | -1.0% | 1.4% |
| 1Y | -3.6% | -20.7% | 25.7% |
Return vs Industry: ZBH exceeded the US Medical Equipment industry which returned -20.7% over the past year.
Return vs Market: ZBH underperformed the US Market which returned 25.7% over the past year.
Price Volatility
| ZBH volatility | |
|---|---|
| ZBH Average Weekly Movement | 4.6% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ZBH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ZBH's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1927 | 17,000 | Ivan Tornos | www.zimmerbiomet.com |
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
Zimmer Biomet Holdings, Inc. Fundamentals Summary
| ZBH fundamental statistics | |
|---|---|
| Market cap | US$17.02b |
| Earnings (TTM) | US$761.20m |
| Revenue (TTM) | US$8.41b |
22.4x
P/E Ratio2.0x
P/S RatioIs ZBH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZBH income statement (TTM) | |
|---|---|
| Revenue | US$8.41b |
| Cost of Revenue | US$2.51b |
| Gross Profit | US$5.90b |
| Other Expenses | US$5.14b |
| Earnings | US$761.20m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.93 |
| Gross Margin | 70.18% |
| Net Profit Margin | 9.05% |
| Debt/Equity Ratio | 59.8% |
How did ZBH perform over the long term?
See historical performance and comparisonDividends
1.1%
Current Dividend Yield25%
Payout RatioDoes ZBH pay a reliable dividends?
See ZBH dividend history and benchmarks| Zimmer Biomet Holdings dividend dates | |
|---|---|
| Ex Dividend Date | Jun 25 2026 |
| Dividend Pay Date | Jul 31 2026 |
| Days until Ex dividend | 3 days |
| Days until Dividend pay date | 39 days |
Does ZBH pay a reliable dividends?
See ZBH dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/21 14:49 |
| End of Day Share Price | 2026/06/18 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zimmer Biomet Holdings, Inc. is covered by 43 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Jeffrey Johnson | Baird |
| Adam Feinstein | Barclays |